NCT06752967 Hormonal Control of Energy and Macronutrient Intake in Obesity (MEMORY)
| NCT ID | NCT06752967 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Steno Diabetes Center Copenhagen |
| Condition | Obesity |
| Study Type | INTERVENTIONAL |
| Enrollment | 45 participants |
| Start Date | 2024-12-12 |
| Primary Completion | 2026-06-29 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 45 participants in total. It began in 2024-12-12 with a primary completion date of 2026-06-29.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The overall aim of the MEMORY study is to examine the concept of 'food memory' - how specific macronutrient compositions influence subsequent food preference and intake, and whether this differs across the BMI range from normal weight to obesity.
Eligibility Criteria
Inclusion Criteria: * Age 18-45 years * For women: Regular menstruation * BMI-range 18.5-39.9 kg/m\^2 Exclusion Criteria: * Not able or willing to eat or drink the test meals because of e.g., allergy or intolerance * Daily smoking * For women: Pregnancy / planned pregnancy (within the study period) / lactating * Self-reported history of an eating disorder * Self-reported weight change (kg) within two months prior to inclusion * HbA1c ≥48 mmol/mol * Treatment with antidepressants * Alcohol/drug abuse or in treatment with disulfiram (antabus) at time of inclusion * Uncontrolled medical issues including but not limited to cardiovascular pulmonary, rheumatologic, hematologic, oncologic, infectious, gastrointestinal, or psychiatric disease; diabetes or other endocrine disease; immunosuppression * Current treatment with medication which significantly affect appetite or energy balance (e.g., GLP-1 receptor agonists) * Bariatric surgery * Unable to understand the informed consent and the study procedures * Concomitant participation in intervention studies * Participant's withdrawal of the informed consent * Other safety concerns - judged by the investigator
Contact & Investigator
Jonas S Salling Quist, MSc, PhD
PRINCIPAL INVESTIGATOR
Steno Diabetes Center Copenhagen
Frequently Asked Questions
Who can join the NCT06752967 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 45 Years, studying Obesity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06752967 currently recruiting?
Yes, NCT06752967 is actively recruiting participants. Contact the research team at jonas.salling.quist@regionh.dk for enrollment information.
Where is the NCT06752967 trial being conducted?
This trial is being conducted at Herlev, Denmark.
Who is sponsoring the NCT06752967 clinical trial?
NCT06752967 is sponsored by Steno Diabetes Center Copenhagen. The principal investigator is Jonas S Salling Quist, MSc, PhD at Steno Diabetes Center Copenhagen. The trial plans to enroll 45 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.